Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Diagnostics
In Vitro Diagnostics
Return to: MDBR Home | Diagnostics | In Vitro Diagnostics

Quidel to buy Alere’s Triage and BNP businesses for $440m

MDBR Staff Writer Published 18 July 2017

Diagnostic testing solutions provider Quidel has agreed to acquire Alere’s Triage and BNP businesses for around $440m.

Under the deal, Quidel will acquire Triage MeterPro cardiovascular (CV) and toxicology assets (Triage business) and the B-type Naturietic Peptide (BNP) assay business run on Beckman Coulter analyzers (BNP business) from Alere.

The product lines are being divested to secure antitrust approvals needed for Abbott’s pending acquisition of Alere.

The sale transactions are subject to the completion of Abbott’s acquisition of Alere, in addition to antitrust approvals and other customary closing conditions.

Through a combination of direct sales force and distributors, Quidel will distribute the Triage MeterPro products and BNP assays.

Triage MeterPro revenues were around $146m in the last year, while BNP business generated $51m for the same period.

Quidel president and CEO Douglas Bryant said: “The Triage acquisition significantly stabilizes our quarterly revenue profile and enhances our geographic and product diversity, with substantial expansion opportunities in new markets.

“Further, while the installed base of Triage MeterPro instruments in the U.S. nicely complements the installed base of our Sofia and Solana platforms in the hospital segment, there will be new call points that our US commercial organization can leverage as well.”

Quidel will acquire Triage business, including real estate for the San Diego Triage facilities.

In April, Abbott amended the existing agreement to acquire diagnostic device and services provider Alere.

As per the amended terms, Abbott will now acquire Alere for a new price of $5.3bn, which is decreased from the originally expected equity value of about $5.8bn.

Both firms have first signed the acquisition deal in February 2016. Under the deal, Abbott agreed to pay $56 per common share in cash to Alere shareholders.

Both firms have first signed the acquisition deal in February 2016. Under the deal, Abbott agreed to pay $56 per common share in cash to Alere shareholders.


Image: Quidel to acquire Alere’s Triage and BNP assets. Photo: courtesy of Stuart Miles / FreeDigitalPhotos.net.